evipedia.ai
← Back

Reishi Mushroom for Health & Longevity

Evidence Review created on 11/05/2026 using AI4L / Opus 5.5

Also known as: Reishi, Lingzhi, Ling Zhi, Ganoderma lucidum, Ganoderma lingzhi, Mannentake, Mushroom of Immortality

Motivation

Reishi mushroom (Ganoderma lucidum, called lingzhi in China) is a woody, glossy fungus sold as dried slices, powders, liquid extracts and spore products. It contains complex sugars and bitter compounds thought to act mainly on the immune system. It is among the most widely used medicinal mushrooms and is marketed for immune support, energy and healthy aging.

Reishi has been part of Chinese and Japanese traditional medicine for about two thousand years, where it was valued as a tonic for vitality and long life rather than as a remedy for a single disease. Interest outside Asia grew once the mushroom could be farmed on a large scale and researchers began testing it in people for fatigue and immune function, and in worms and mice for effects on lifespan.

This review examines what human trials, reviews and laboratory studies report about reishi’s benefits and risks for health-focused adults who want to extend healthy lifespan. It also covers liver safety, drug interactions, product quality, dosing and monitoring, and how strong the evidence behind each claim is.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of reishi from expert commentary, a podcast and a narrative review.

  • What is Reishi? - Laurie Mathena

    An accessible overview of reishi’s immune, metabolic and mouse-lifespan claims with references. Life Extension sells a reishi product, so the framing is promotional rather than critical.

  • RHR Research Review: Medicinal Mushrooms, Gut Microbiota, Blood Sugar, Root-Causeism, and Nutrient Deficiency - Chris Kresser

    A practitioner’s overview of medicinal mushrooms, centered on beta-glucans and terpenes, the immune-active compound classes in reishi, with a short passage on reishi. Kresser’s site promotes his own supplement line.

  • Reishi Mushroom - Ting Bao & Jyothirmai Gubili

    A concise integrative-oncology summary from Memorial Sloan Kettering clinicians covering mechanisms, clinical findings, adverse effects and drug interactions, written for oncology professionals.

  • Emerging Roles of Ganoderma lucidum in Anti-Aging - Wang et al., 2017

    A narrative review cataloguing which reishi extracts and compounds extended lifespan or modified aging-related pathways in yeast, worms and rodents, and the gaps before clinical use.

Only four items are listed. Peter Attia, Andrew Huberman and Lifespan.io have no reishi-specific content: site and web searches returned none. Rhonda Patrick mentions reishi only briefly in a members-only FoundMyFitness Q&A (2018), which is paywalled and not an in-depth overview. Other candidates were databases, encyclopedias or mainstream media.

Grokipedia

  • Lingzhi (mushroom)

    An encyclopedic overview of reishi’s biology, traditional use, bioactive compounds, preparation forms and reported pharmacology, useful for orientation and terminology.

Examine

  • Reishi

    Summarizes reishi’s research, evidence grades and dosing by preparation (1.44–5.2 g extract; 6 mg ethanol extract); detailed outcome grades require membership.

ConsumerLab

  • Reishi (Mushroom) Supplements Review

    Independent laboratory testing of seven reishi supplements for beta-glucan, triterpene and heavy-metal content; two failed on beta-glucan, and mycelium-on-grain products are flagged. Top picks are member-only.

Systematic Reviews

This section lists systematic reviews and meta-analyses of reishi in cancer care, cardiometabolic risk, general health markers and drug co-use. No systematic review covers liver injury, the principal serious risk; the interaction review below addresses co-use safety only.

Mechanism of Action

Reishi’s activity is attributed to two compound classes that behave differently in the body.

  • Polysaccharides (beta-glucans): Large branched glucose chains that are poorly absorbed. They are thought to act on gut-associated immune cells by binding dectin-1 (an immune-cell receptor that recognizes fungal beta-glucans) and TLR4 (toll-like receptor 4, a sensor of microbial molecules), activating macrophages, dendritic cells and natural killer (NK) cells. In mice, high-molecular-weight polysaccharides also reshaped gut bacteria and limited diet-induced weight gain (Chang 2015); several co-authors were affiliated with Chang Gung Biotechnology, a reishi producer.
  • Triterpenes (ganoderic acids): Bitter, alcohol-soluble compounds that are absorbed. In healthy men they peaked about 30 minutes after a dose, were eliminated with half-lives under 40 minutes, and food lowered peak levels (Teekachunhatean 2012). Laboratory work links them to inhibition of NF-κB (a master switch for inflammatory genes) and of 5α-reductase (the enzyme converting testosterone to the more potent dihydrotestosterone), the rationale for prostate trials.
  • Longevity pathways: In worms and human cells, a water extract induced autophagy (cellular recycling) and lowered mTOR (a nutrient-sensing growth pathway) activity (Peng 2021); the authors include the same company’s staff.
  • Pharmacology gaps: Tissue distribution in humans is unknown. In rat liver tissue, polysaccharides inhibited CYP2E1, CYP1A2 and CYP3A (drug-metabolizing liver enzymes) (Wang 2007); human relevance is untested.
  • Competing views: Reishi is marketed as an immune “modulator”, yet a scoping review links this activation to autoimmune flares (Weiner 2025). Whether polysaccharides act systemically or only through the gut remains unresolved.

Historical Context & Evolution

  • Original use: Lingzhi appears in the Shen Nong Ben Cao Jing, an early Chinese materia medica, among “superior” herbs taken over long periods to sustain vitality and long life rather than to treat a specific disease. Wild specimens were scarce and associated with Daoist ideas of immortality.
  • Route to health optimization: Commercial cultivation from the 1970s made reishi cheap and plentiful. Japanese and Chinese laboratories then isolated polysaccharides and triterpenes with immune and anti-tumor activity in animals, and reishi was marketed internationally as an immune tonic and “mushroom of immortality.”
  • Early human findings: An uncontrolled study reported higher natural killer-cell activity in advanced cancer (Gao 2003); a placebo-controlled trial reported less fatigue in neurasthenia (a chronic fatigue-and-irritability syndrome) (Tang 2005); and a Hong Kong supplementation study in healthy adults found no change in antioxidant, lipid, immune or toxicity markers (Wachtel-Galor 2004).
  • Evolution of opinion: Cochrane reviews judged the cancer trials low quality (Jin 2016) and found no cardiometabolic benefit (Klupp 2015), and a 2016 trial matched that null result (Klupp 2016). These reviews did not test the traditional tonic and fatigue claims, which remain open. DNA work later showed most commercial “G. lucidum” is Ganoderma lingzhi (Loyd 2018), complicating comparison across trials, while worm and mouse lifespan studies renewed longevity interest.

Expected Benefits

High 🟩 🟩 🟩

Fatigue, Mood & Well-Being ⚠️ Conflicted

Three independent groups report less fatigue or better mood: Tang (132 people with neurasthenia; polysaccharide extract), Zhao (48 breast cancer patients; spore powder versus an unblinded control) and Mitra (78 female students; 1,000 mg/day). All trials were small, lasted 4–8 weeks and used concentrated preparations. In 10 men with Gulf War illness (a chronic fatigue-and-pain condition in veterans), the higher reishi dose worsened symptom severity versus placebo (Younger 2021). Net reading: a modest, replicated short-term improvement, with one small trial pointing the other way.

Magnitude: In Tang 2005, 51.6% of the extract group versus 24.6% of the placebo group were rated more than minimally improved on the CGI (Clinical Global Impression, a clinician-rated severity scale) after 8 weeks; fatigue scores fell 28.3% with extract and 20.1% with placebo, reported as significantly lower with extract (no between-group difference figure given). Supporting trials: Zhao 2012, Mitra 2024.

Medium 🟩 🟩

Physical Capacity

One trial shows better physical performance versus placebo: Mitra found higher VO2max (maximal oxygen uptake, a validated fitness measure) at 1,000 mg/day. Collado Mateo found improved aerobic endurance, flexibility and walking speed within the reishi group in 64 women with fibromyalgia (a chronic widespread-pain disorder) taking 6 g/day for 6 weeks, but did not compare it with the carob-flour group. A meta-analysis of athlete trials reported lower blood lactate and urea and higher hemoglobin with reishi but no pooled performance outcome (Shu 2025). Both trials were small and short.

Magnitude: Direction only: VO2max, physical work capacity and resting heart rate improved at 1,000 mg/day but not 500 mg/day versus placebo (Mitra 2024); aerobic endurance, flexibility and speed improved within the reishi group, while the carob-flour group did not improve (no between-group comparison reported) (Collado Mateo 2015); the published abstracts report significance levels but no between-group outcome figure.

Lower Urinary Tract Symptoms in Men

In men over 49 with mild-to-moderate LUTS (lower urinary tract symptoms such as frequency, urgency and weak stream), a reishi ethanol extract chosen for its 5α-reductase inhibition improved symptom scores. Both placebo-controlled trials came from one group at Kurume University and used milligram doses of a specific extract (0.6–60 mg/day dose-ranging, then 6 mg/day), so the findings may not apply to standard products. Urinary flow, prostate volume and PSA (prostate-specific antigen, a prostate blood marker) did not change (Noguchi 2008), nor did testosterone (Noguchi 2008).

Magnitude: The IPSS (International Prostate Symptom Score, 0–35) improved 1.18 points more than placebo after 12 weeks (95% CI [confidence interval, the range of plausible true values] −1.74 to −0.62) in 88 men (Noguchi 2008).

Adjunct Support During Cancer Treatment

A Cochrane meta-analysis of five randomized trials found that cancer patients given reishi alongside chemotherapy or radiotherapy more often had tumor shrinkage, reported better quality of life in four trials, and showed small rises in T-cell percentages. The authors rated trial quality as unsatisfying and no trial measured survival. A pooled analysis reporting lower mortality combined reishi with turkey tail mushroom (Trametes versicolor) products and cannot isolate reishi (Zhong 2019). The data do not support reishi as a stand-alone cancer treatment.

Magnitude: Tumor response RR (relative risk, the ratio of response rates between groups) 1.50 (95% CI 0.90 to 2.51) with reishi plus chemotherapy or radiotherapy versus conventional treatment alone; the interval includes no effect although the review reports P = 0.02 (P, how likely such a result is by chance alone) (Jin 2016).

Low 🟩

Cardiometabolic Markers ⚠️ Conflicted

A Cochrane review (Klupp 2015) and a 16-week placebo-controlled trial (Klupp 2016) found no effect on glucose, lipids or blood pressure. A 2025 meta-analysis found small body-weight and heart-rate reductions at very low certainty; in mice, gut-bacteria shifts limited weight gain (Chang 2015). Net reading: no reliable cardiometabolic effect.

Magnitude: HbA1c (glycated hemoglobin, a three-month glucose average) changed −0.10% versus placebo (95% CI −1.05 to 0.85) (Klupp 2015); BMI (body mass index) fell 0.43 kg/m² more than control (95% CI −0.77 to −0.10) (Jafari 2025).

Liver Enzymes and Fatty Liver ⚠️ Conflicted

In a 6-month crossover trial in 42 healthy adults, an enriched extract lowered AST and ALT (aspartate and alanine aminotransferase, liver-cell injury markers) and improved mild fatty liver on ultrasound (Chiu 2017). A 2025 meta-analysis found no liver-enzyme effect. Net reading: unconfirmed.

Magnitude: No significant pooled change in liver enzymes across trials (Jafari 2025); in Chiu 2017, ALT fell from 22.58 to 13.08 U/L and AST from 20.65 to 15.50 U/L over 6 months with extract, versus 20.05 to 21.33 and 19.65 to 19.90 U/L with placebo (not compared between groups); the abstract’s “42 and 27%” assigns the larger fall to AST, but the full-text table shows it for ALT (Chiu 2017).

Kidney Function Marker (Creatinine)

A meta-analysis of randomized trials found lower serum creatinine (a waste product cleared by the kidneys) with reishi. Certainty was very low, and removing any of three trials made the result non-significant. Creatinine also reflects muscle mass, so a kidney benefit is indirect.

Magnitude: Serum creatinine 0.14 lower than control (95% CI −0.27 to −0.02; units not stated in the review text), pooled from 361 participants (Jafari 2025).

Colorectal Adenoma Regression

In a 12-month non-randomized controlled trial, 96 patients taking a water-soluble extract of reishi mycelium culture medium had fewer and smaller colorectal adenomas (precancerous polyps) than 102 untreated controls. This product differs in form from fruiting-body reishi (indirect evidence), and no replication exists.

Magnitude: Mean adenoma count changed −0.42 with extract versus +0.66 in controls over 12 months (P < 0.01) (Oka 2010).

Speculative 🟨

Lifespan Extension

Water extract extended lifespan in the nematode worm Caenorhabditis elegans through autophagy, and lowered mTOR signaling in human cells (Peng 2021). No human lifespan data exist; the basis is animal and cell work.

Immune-Cell Activation ⚠️ Conflicted

Placebo-controlled trials in healthy adults (Chen 2023) and older women (Iser-Bem 2024) report T-cell and NK-cell changes; another found no lymphocyte-subset difference (Chu 2012). These are unvalidated biomarkers. Net reading: inconsistent, clinically unproven immune effects.

Antioxidant Capacity ⚠️ Conflicted

One trial raised plasma antioxidant capacity (Chiu 2017) and a meta-analysis glutathione peroxidase (an antioxidant enzyme) (Jafari 2025); two found no plasma change (Wachtel-Galor 2004; Chu 2012). Net reading: inconsistent changes in unvalidated biomarkers.

Sleep Promotion

In mice, a mycelium extract shortened time to fall asleep through gut-bacteria-dependent serotonin signaling (Yao 2021). No controlled human sleep trial has reported results; the basis is animal work.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined gene variants that alter response; because polysaccharides act through gut bacteria in animals (Chang 2015), individual microbiome composition may matter more than genotype.
  • Baseline biomarkers: Benefits appeared mainly in symptomatic groups (fatigue, urinary symptoms, fibromyalgia). In a meta-analysis, BMI fell overall, and BMI and cholesterol improvements were concentrated in subgroups on lower doses (<1,400 mg/day) or under 50 years (Jafari 2025).
  • Sex: Urinary-symptom data come only from men; fitness and fatigue data largely from women. No trial compared sexes directly.
  • Pre-existing conditions: Signals arose in neurasthenia, cancer, fibromyalgia and enlarged-prostate symptoms; healthy adults showed few measurable changes (Wachtel-Galor 2004). People with Gulf War illness may worsen (Younger 2021).
  • Age: In women over 60, 2,000 mg/day shifted T-cell function toward an anti-inflammatory profile (Iser-Bem 2024); whether this alters infection risk in older adults is untested.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from small placebo-controlled trials that found no excess over placebo, and serious harms rest on case reports.

Medium 🟥 🟥

Symptom Worsening in Gulf War Illness

In a placebo-controlled, pseudo-randomized crossover trial in men with Gulf War illness (a chronic condition of fatigue, pain and cognitive complaints in veterans), the higher reishi dose increased overall symptom severity versus placebo in the 10 men given reishi, while the lower dose did not differ. The authors tested reishi as a modulator of microglia (brain immune cells); the mechanism of worsening is unknown. This is a single small trial in a specific population.

Magnitude: Mean symptom severity was 38.5 with higher-dose reishi versus 35.0 with placebo (P = 0.012), and 35.2 with lower-dose reishi (P = 0.603 versus placebo) (Younger 2021).

Low 🟥

Minor Gastrointestinal and Other Adverse Effects ⚠️ Conflicted

Dry mouth, constipation, nausea, insomnia, itching and dizziness are reported by users; a survey co-author works for Zhongke Health Industry Group, which patents reishi spore-powder processing. Placebo-controlled trials found no significant excess (Wicks 2007). Net reading: mild effects, not clearly above placebo.

Magnitude: Adverse events RR 1.67 versus placebo (95% CI 0.86 to 3.24) over 4 months in a Cochrane review (Klupp 2015); 9.1% of 1,374 users reported adverse effects, led by dry mouth (5%) (no control group) (Li 2024).

Liver Injury ⚠️ Conflicted

Case reports describe acute hepatitis, one fatal, after switching to powdered reishi (Yuen 2004; Wanmuang 2007), reishi with alcohol (Guedikian 2023), and eosinophilic (allergy-type white cell) liver nodules (Kogure 2021). Small trials found no enzyme rise. Net reading: rare, unquantified risk.

Magnitude: Not quantified in available studies. Only case reports exist, so no incidence can be estimated; controlled trials (Wachtel-Galor 2004) were too small to detect rare reactions.

Bleeding Tendency ⚠️ Conflicted

An uncontrolled study found reduced platelet aggregation after 2 weeks of reishi in patients with atherosclerosis (artery plaque disease). A placebo-controlled trial in 40 healthy volunteers found no change in coagulation or platelet function after 4 weeks. Net reading: no bleeding effect shown in healthy people.

Magnitude: Maximum ADP-induced (adenosine diphosphate, a platelet activator) aggregation fell 31.49% (no control group) (Tao 1990); no between-group difference in any hemostatic test versus placebo (Kwok 2005).

False Tumor-Marker Elevation

Case series describe rises in CA72-4 (a gastrointestinal-cancer tumor marker) after 1–2 months of spore powder, normalizing after stopping and prompting unnecessary investigations (Yan 2014; Liang 2013). The mechanism is unknown.

Magnitude: Not quantified in available studies. Only case series of eight patients exist, so no frequency can be estimated.

Respiratory Allergy to Spores

Among 172 allergy-prone patients in Delhi, many reacted on skin testing to Ganoderma spore extract and had raised IgE (allergy antibodies). This reflects inhaled outdoor spores, not oral supplements (indirect route).

Magnitude: 28.48% skin-test positivity to spore extract (no control group) (Singh 1995).

Bone-Marrow Suppression

A case report describes aplastic crisis (sudden failure of the bone marrow to make blood cells) attributed to reishi, accompanied by blistering hand dermatitis and hair loss (Choi 2013). The mechanism is unknown. This is a single isolated report, with no controlled data.

Magnitude: Not quantified in available studies. Only a single case report exists, so no incidence can be estimated.

Speculative 🟨

Autoimmune Flare

A scoping review lists reishi among 15 immunostimulatory herbs that may trigger or worsen autoimmune skin diseases such as lupus (Weiner 2025). The basis is mechanistic and isolated reports.

Risk-Modifying Factors

  • Genetic polymorphisms: No variants are known to predict reishi liver injury or other harms; liver reactions appear idiosyncratic, and no pharmacogenetic study exists.
  • Baseline biomarkers: Pre-existing raised liver enzymes complicate detection of reishi-related injury. In people monitored with CA72-4, spore products can create false alarms (Yan 2014).
  • Sex: No sex differences in adverse effects have been reported. Pregnancy and breastfeeding lack safety data.
  • Pre-existing conditions: Liver disease, alcohol use (Guedikian 2023), autoimmune disease, organ transplantation, Gulf War illness and fungal allergy plausibly raise risk; reported liver cases often involved other medicines.
  • Age: Older adults more often take anticoagulants (blood-thinning drugs), diabetes drugs and multiple medicines, raising interaction potential; women over 60 tolerated 2,000 mg/day for 8 weeks (Iser-Bem 2024).

Key Interactions & Contraindications

Documented interactions:

  • Food: A meal lowered peak ganoderic acid levels, delayed absorption and markedly reduced absorption of ganoderic acid F (Teekachunhatean 2012). Consequence: lower triterpene exposure; mitigation: fasting intake when triterpene exposure is the aim.
  • Ascorbic acid (vitamin C): 2,500 mg ascorbic acid with 3,000 mg reishi water extract did not alter ganoderic acid A pharmacokinetics in 12 healthy men; no interaction found (Tawasri 2016).
  • Cytotoxic chemotherapy (cisplatin, 5-fluorouracil, paclitaxel): A systematic review of 21 clinical studies of combined use found no reported adverse interactions, but none measured drug levels (Lam 2020); no interaction found to date. Mitigation: coordination with the treating oncologist.
  • Cordyceps (Cordyceps sinensis): Combining 3 g/day reishi with cordyceps for 16 weeks caused no excess adverse events versus placebo in adults with diabetes; no interaction found (Klupp 2016).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Anticoagulants and antiplatelet drugs (drugs that slow clotting or block platelet clumping: warfarin, apixaban, clopidogrel): Additive antiplatelet effect inferred from platelet-aggregation data (Tao 1990); consequence: increased bleeding. Mitigation: INR (international normalized ratio, a clotting test) check after starting or stopping reishi on warfarin.
  • Over-the-counter aspirin and NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen): Additive platelet inhibition inferred from the same data; consequence: bleeding or bruising. Mitigation: occasional rather than daily NSAID use.
  • Acetaminophen (paracetamol) at high doses and other liver-stressing drugs (methotrexate): Additive liver stress inferred from reishi liver-injury case reports; consequence: hepatitis. Mitigation: liver enzyme checks.
  • Alcohol: Additive liver stress; supported only by a single case report of hepatitis after reishi powder with alcohol (Guedikian 2023), not an interaction study. Mitigation: limiting alcohol during use.
  • Glucose-lowering drugs (metformin, insulin, glimepiride): Additive glucose lowering inferred from animal data; a Cochrane review of trials found no glucose change (Klupp 2015). Consequence: hypoglycemia (low blood sugar). Mitigation: home glucose checks in the first weeks.
  • Antihypertensives (blood pressure-lowering drugs: lisinopril, amlodipine): Additive blood pressure lowering inferred from traditional antihypertensive use; trials found no blood pressure change. Consequence: dizziness or low blood pressure. Mitigation: home blood pressure readings.
  • Immunosuppressants (drugs that dampen immune activity: tacrolimus, cyclosporine, mycophenolate): Opposing effect inferred from immune-cell activation (Chen 2023); consequence: weakened immunosuppression and possible rejection or disease flare. Mitigation: avoidance during immunosuppressive therapy.
  • CYP2E1, CYP1A2 and CYP3A substrates (chlorzoxazone, theophylline, midazolam): Enzyme inhibition seen in rat liver tissue (Wang 2007); consequence: raised drug levels. Mitigation: drug-level monitoring for narrow-margin drugs.
  • Immune-stimulating supplements (echinacea, astragalus, turkey tail): Additive immune stimulation inferred from shared beta-glucan and cytokine effects; consequence: higher autoimmune flare potential. Mitigation: avoiding stacking in autoimmune disease.
  • Antiplatelet and glucose-lowering supplements (fish oil, ginkgo, garlic, berberine): Additive bleeding or glucose-lowering effects inferred from each agent’s mechanism; consequence: bruising or hypoglycemia. Mitigation: introducing one agent at a time.

Populations who should avoid Reishi Mushroom:

  • Prior reishi-associated liver injury or active liver disease: Inferred from case reports of hepatitis, including a death, with powdered reishi (Wanmuang 2007); no controlled data.
  • Autoimmune skin disease (lupus, dermatomyositis, an autoimmune muscle-and-skin disease): Inferred from immune-stimulating activity; a scoping review lists reishi among herbs that may flare these conditions (Weiner 2025); no human data on harm.
  • Organ-transplant recipients on immunosuppressants: Inferred from immune-cell activation opposing immunosuppression; no human data.
  • Patients monitored with CA72-4 (gastric, colorectal, ovarian cancer): Spore products caused false marker rises (Yan 2014).
  • Pregnancy and breastfeeding: Inferred from immunomodulatory activity and absent safety data; no human data on harm.
  • Known Ganoderma or fungal-spore allergy: Spore sensitization documented in allergy-prone patients (Singh 1995).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Liver enzyme checks: Mitigates liver injury. ALT and AST before starting, again at 4–8 weeks, then every 6–12 months; stopping at jaundice, dark urine or unexplained fatigue, as in reported cases (Guedikian 2023).
  • Extract over raw powder: Mitigates liver injury; both early hepatitis cases followed a switch from boiled reishi to powder (Wanmuang 2007).
  • Low start: Mitigates gastrointestinal effects and dry mouth: 1–1.5 g/day extract for 1–2 weeks before reaching the target dose.
  • Disclosure to oncology and laboratory teams: Prevents misread CA72-4 rises from spore products (Liang 2013); pausing spores 2–4 weeks before tumor-marker testing.
  • Pause before surgery: Mitigates theoretical bleeding risk: stopping 1–2 weeks before elective surgery, although a trial found no hemostatic effect (Kwok 2005).
  • Medication-specific monitoring: Mitigates bleeding and hypoglycemia: INR within 1–2 weeks of starting on warfarin; home glucose checks on glucose-lowering drugs.
  • Tested products: Mitigates contamination and mislabeling: third-party tested, fruiting-body products (ConsumerLab reishi review).
  • Autoimmune vigilance: Mitigates autoimmune flare: stopping at new rash, joint pain or disease flare.

Therapeutic Protocol

Timing, titration, splitting and cycling below reflect common practice unless cited.

  • Standard extract dose: 1.44–5.2 g/day of whole extract (Examine reishi page); the fatigue trial used 1,800 mg three times daily, 5.4 g/day (Tang 2005).
  • Cardiometabolic and safety trials: 1.44 g/day (Chu 2012) and 3 g/day (Klupp 2016) of fruiting-body preparations.
  • Low-dose regimens: 225 mg/day of a triterpene- and polysaccharide-enriched extract (Chiu 2017); 1,000 mg/day for fitness and mood (Mitra 2024); 6 mg/day ethanol extract for urinary symptoms (Noguchi 2008).
  • Competing approaches: Traditional practice uses hot-water decoctions of dried fruiting body; supplement makers favor concentrated extracts (5 g extract ≈ 50 g whole mushroom, Examine reishi page) or spore powder (4 g/day in NCT07524777).
  • Popularizers: Life Extension, which sells a reishi product (Life Extension Magazine reishi article), and Chris Kresser, whose site promotes his supplement line (Kresser RHR episode), promote daily extract use; the three-times-daily polysaccharide regimen came from Ganopoly trials (Tang 2005).
  • Time of day: No trial compared timing; evening use follows the traditional calming reputation, while triterpene absorption is best fasting (Teekachunhatean 2012).
  • Half-life: Ganoderic acids have elimination half-lives under 40 minutes (Teekachunhatean 2012); polysaccharide kinetics in humans are unknown.
  • Single versus split dosing: Split dosing two to three times daily is usual given the short triterpene half-life; once-daily regimens were also used in trials.
  • Genetic polymorphisms: No pharmacogenetic data guide dose; no gene variant is known to alter response or tolerance.
  • Sex: No sex-specific dosing exists; urinary-symptom dosing applies to men only.
  • Age: Older women tolerated 2,000 mg/day (Iser-Bem 2024); in older adults with multiple medicines, lower starting doses limit interaction risk.
  • Baseline biomarkers: Raised baseline liver enzymes argue for closer monitoring; a Cochrane review found no glucose or lipid change in type 2 diabetes (Klupp 2015).
  • Pre-existing conditions: In cancer, preparation choice is coordinated with oncology; spore products are avoided when CA72-4 is monitored (Yan 2014).

Discontinuation & Cycling

  • Duration: Traditionally taken long-term as a tonic; controlled data cover 4 weeks to 12 months (Oka 2010), so safety beyond one year is unstudied.
  • Withdrawal effects: None reported in trials or case series.
  • Tapering: Not required; reishi can be stopped abruptly. Patients on warfarin or glucose-lowering drugs recheck INR or glucose after stopping.
  • Cycling: No evidence shows cycling maintains efficacy or reduces risk; some practitioners use breaks of 1–2 weeks every 2–3 months as a precaution.
  • Stopping triggers: Jaundice, dark urine, new rash, unusual bruising, symptom worsening, or upcoming surgery or tumor-marker testing.

Sourcing and Quality

  • Fruiting body versus mycelium: Products listing “mycelial biomass” grown on grain may contain mostly grain starch (alpha-glucan) rather than reishi beta-glucan; ConsumerLab treats “mushroom” or “fruiting body” listed first as the marker of real reishi content (ConsumerLab reishi review).
  • Active-compound content: In 2026 testing, two of seven products failed for low beta-glucan, and three of five approved products were low in triterpenes (ConsumerLab reishi review).
  • Species identity: DNA testing found 93% of manufactured “reishi” products contained Ganoderma lingzhi, none true G. lucidum, and some contained other species (Loyd 2018).
  • Spore products: A systematic review reports greater activity for sporoderm-broken (cracked-wall) than intact spores, mainly in laboratory work (Thuy 2023); spore powder carries the CA72-4 interference.
  • Third-party testing: ConsumerLab, USP (United States Pharmacopeia) or NSF International certification, plus a certificate of analysis stating beta-glucan and triterpene content.
  • Brands: ConsumerLab’s 2026 review tested Host Defense, Real Mushrooms, Life Extension, Swanson, Freshcap, Om and BulkSupplements; its approval list and top pick are member-only (ConsumerLab reishi review).
  • Contaminants: No tested product failed heavy-metal limits in 2026 (ConsumerLab reishi review); wild-harvested material is less controlled.

Practical Considerations

  • Time to effect: Urinary-symptom benefits separated from placebo by weeks 4–8 (Noguchi 2008); fatigue benefits at 4–8 weeks (Tang 2005); fitness changes by 30 days (Mitra 2024).
  • Common pitfalls: Buying mycelium-on-grain products; expecting cholesterol, glucose or blood pressure improvements, which trials did not show; switching to raw powder; and forgetting spore use before tumor-marker tests.
  • Regulatory status: Sold in the US as a dietary supplement. Under DSHEA (Dietary Supplement Health and Education Act), makers are responsible for pre-market safety and labeling; the FDA (US Food and Drug Administration) acts only after products reach market (FDA dietary supplements page).
  • Cost and access: Widely available and inexpensive; cost is not a barrier.
  • Preparation variability: Water extracts concentrate polysaccharides, alcohol extracts concentrate triterpenes, so results from one preparation may not transfer to another (Examine reishi page).

Interaction with Foundational Habits

  • Sleep: Possibly potentiating or blunting (conflicting signals). Mouse data suggest sleep promotion via gut-bacteria-linked serotonin (Yao 2021), yet insomnia is reported as an adverse effect (Li 2024). Moving doses to morning is a common adjustment when sleep worsens; the only human sleep trial has not reported.
  • Nutrition: Direct interaction. Food reduces triterpene absorption (Teekachunhatean 2012). Polysaccharides act as fermentable fiber in animals (Chang 2015), so a fiber-rich diet is complementary. Heavy alcohol intake adds liver stress (Guedikian 2023). No nutrient depletion is known.
  • Exercise: Potentiating in small trials: better aerobic capacity (Mitra 2024) and lower blood lactate in athletes in a meta-analysis (Shu 2025). No data show blunted training adaptation; timing around workouts is unstudied.
  • Stress management: Possibly potentiating. Anxiety and well-being scores improved at 1,000 mg/day (Mitra 2024), but urinary cortisol and catecholamines (stress hormones) did not change in a 12-week trial (Chu 2012). Reishi complements, not replaces, behavioral stress practices.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference values for liver function, blood counts and, where relevant, clotting and glucose. A liver panel and complete blood count with differential are the core safety tests; INR is added for warfarin users and fasting glucose or HbA1c for people on glucose-lowering drugs. People with gastrointestinal or ovarian cancer who are followed with CA72-4 record a value before using spore products.

Ongoing monitoring follows this cadence: liver panel at 4–8 weeks, then every 6–12 months; INR within 1–2 weeks of starting or stopping reishi on warfarin; glucose checks during the first 2–4 weeks on glucose-lowering drugs. Success is judged on symptoms the trials measured, such as fatigue, exercise tolerance and urinary symptoms, reassessed after 8–12 weeks against the individual’s own baseline.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT and AST ALT about 7–55 U/L; AST about 8–48 U/L (standard reference range) Safety check: liver injury stops use Case reports of hepatitis (Wanmuang 2007); no fasting needed; ranges vary by laboratory
Bilirubin (total) About 0.1–1.2 mg/dL (standard reference range) Safety check: rise with ALT signals significant liver injury Paired with ALT and AST in a liver panel
Eosinophil count About 0–500 cells/µL (standard reference range) Safety check: hypereosinophilia stops use Hypereosinophilia (very high allergy-type white cells) with liver nodules reported (Kogure 2021); part of a complete blood count (CBC) with differential
INR (warfarin users only) No established target; track change from the individual’s own pre-reishi INR Safety check: change prompts warfarin dose review Theoretical antiplatelet interaction (Tao 1990); test 1–2 weeks after starting or stopping
Fasting glucose or HbA1c (glucose-lowering drug users only) Fasting glucose about 70–99 mg/dL; HbA1c below 5.7% (standard reference range) Safety check: hypoglycemia prompts drug review Fasting morning sample; trials found no glucose change (Klupp 2016)
CA72-4 (only if already monitored for cancer) About ≤6.9 U/mL (standard reference range; assay-specific) Safety check: false rise from spore products alters interpretation Normalizes after stopping spores (Yan 2014)

Qualitative markers:

  • Fatigue and energy levels across the day
  • Mood, anxiety and sense of well-being
  • Exercise tolerance and recovery
  • Sleep quality and time to fall asleep
  • Urinary frequency, urgency and stream (men)
  • Gastrointestinal tolerance, dry mouth, itching or rash
  • Unusual bruising or bleeding

Emerging Research

  • Cancer-related fatigue trial (NCT06028022): Mayo Clinic Phase 2 randomized trial of reishi extract in 80 women on aromatase inhibitors (estrogen-lowering breast-cancer drugs); primary endpoint fatigue change; recruiting, completion 2029. A positive result would strengthen the fatigue item; a null result would weaken it.
  • Fatty liver trial (NCT07534241): 102 adults with metabolic dysfunction-associated fatty liver disease, 250 mg reishi powder once or twice daily versus starch; primary endpoint lipid profile; recruiting, completion December 2026. Positive results would support the liver and lipid items; null results would reinforce the cardiometabolic null reading.
  • Antioxidant response in fatty liver (NCT07564947): 40 participants, reishi powder versus placebo; primary endpoint plasma total antioxidant capacity; enrolling by invitation, completion April 2027. A positive result would add biomarker data only; a null result would weaken the antioxidant item.
  • Sleep trial (NCT07294482): 100 participants, 1:4 liquid extract; endpoints stress, fatigue and sleep disturbance. Registered completion September 2026 has passed; the record still lists recruiting and no results are posted. Positive results would give the first human sleep evidence; null results would weaken it.
  • Depression in thyroid cancer (NCT07524777): 300 participants, spore powder 4 g/day versus placebo for 3 months; primary endpoint HAMD-24 (Hamilton Depression Rating Scale, a clinician-rated depression score). Completed July 2026, no results posted. Positive results would strengthen the mood item; null results would weaken it.
  • Early Parkinson disease (NCT03594656): Phase 3, 288 participants, 0.8 g twice daily versus placebo; motor-score endpoints; completion December 2021 passed, status unknown, no results posted. A positive result would add a neuroprotection benefit; a null result would leave none.
  • Human aging biomarkers: Autophagy and mTOR effects in worms and cells (Peng 2021) have not been tested with human aging clocks or physical-function outcomes; such trials could move lifespan claims beyond Speculative.
  • Product standardization: Species and compound variability (Loyd 2018) undermines pooling; trials using DNA-verified, compound-standardized products could clarify or erase current signals.
  • Safety signals: Liver-injury reports continue (Guedikian 2023), and symptom worsening in Gulf War illness (Younger 2021) suggests some groups respond adversely; systematic adverse-event surveillance could weaken the case for routine use.

Conclusion

Reishi is a medicinal mushroom with a long traditional reputation as a tonic for vitality and long life, now sold mostly as concentrated extracts and spore products. For health-focused adults, the human evidence points to modest benefits for tiredness and mood, from several small, short studies in different groups, with one small study in which symptoms worsened. Support for better physical stamina, for easing urinary symptoms in older men and for quality of life during cancer treatment is weaker, and the claimed improvements in blood sugar, cholesterol and blood pressure were not borne out in the better-designed studies.

Its reputation for lengthening life rests on worm and mouse experiments and on immune and antioxidant blood markers whose meaning for health is unknown. No study has tested whether reishi helps people live longer or stay healthier with age.

Most users report few or mild side effects, and controlled studies have not shown more problems than with placebo. Rare liver injury, including one death, has been reported with powdered forms, spore products can falsely raise a cancer blood marker, and immune activation is a concern in autoimmune disease and in people taking drugs that suppress the immune system.

The evidence base is small, often low in quality, and partly produced by researchers linked to reishi manufacturers and sellers. Products also vary widely in species and active content, so results from one product may not apply to another.

Top - Benefits - Risks - Protocol